Related Experiment Video
Updated: Jul 26, 2025
08:09
Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
Published on: January 7, 2014
7.6K
Targeting gasdermin E in neurodegenerative diseases
Zhi Dong Zhou1, Ling Xiao Yi2, Eng King Tan3
1National Neuroscience Institute of Singapore, 11 Jalan Tan Tock Seng, Singapore, 30843, Singapore; Signature Research Program in Neuroscience and Behavioral Disorders, Duke-NUS Medical School, 8 College Road, Singapore, 169857, Singapore.
Cell Reports. Medicine
|June 21, 2023
Summary
Gasdermin-E (GSDME) shows links to frontotemporal dementia and amyotrophic lateral sclerosis. Targeting GSDME may offer new treatments for these neurodegenerative diseases.
Area of Science:
- Neuroscience
- Molecular Biology
- Genetics
Background:
- Frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) are debilitating neurodegenerative diseases with complex etiologies.
- Gasdermin-E (GSDME) is a protein implicated in pyroptosis, a form of programmed cell death.
Purpose of the Study:
- To investigate the potential role of gasdermin-E (GSDME) in the pathophysiology of FTD and ALS.
- To explore GSDME as a therapeutic target for neurodegenerative conditions.
Main Methods:
- Analysis of existing literature and data linking GSDME to neuroinflammation and neuronal cell death.
- Review of studies on GSDME's involvement in cellular processes relevant to FTD and ALS.
Main Results:
- Identification of pathophysiologic links between GSDME and the mechanisms underlying FTD and ALS.
- Evidence suggesting GSDME dysregulation contributes to neurodegeneration in these conditions.
Conclusions:
- Gasdermin-E (GSDME) represents a significant molecular link in the development of FTD and ALS.
- Targeting GSDME therapeutically holds promise for novel treatment strategies for neurodegenerative diseases.
Related Concept Videos
01:37Neural Regulation
39.6K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.6K
01:15Parkinson's Disease: Overview
611
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
611
01:22Alzheimer's Disease: Treatment
223
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
223
01:26Alzheimer's Disease: Overview
532
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
532
01:29Drugs Affecting Neurotransmitter Synthesis
1.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K
01:24Parkinson's Disease: Treatment
303
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
303